Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users

Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users

Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland‐van der Zee AH, on behalf of the EU‐PACT group. Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012; 10: 2610–2.

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of thrombosis and haemostasis 2012-12, Vol.10 (12), p.2610-2612
Hauptverfasser: VERHOEF, T. I., REDEKOP, W. K., HEGAZY, H., DE BOER, A., MAITLAND‐van der ZEE, A. H.
Format: Artikel
Sprache:eng
Schlagworte:
Anticoagulants
Anticoagulants - therapeutic use
Aryl Hydrocarbon Hydroxylases - genetics
Cytochrome P-450 CYP2C9
Genotype
Humans
Mixed Function Oxygenases - genetics
Phenprocoumon - therapeutic use
Vitamin K Epoxide Reductases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2612
container_issue 12
container_start_page 2610
container_title Journal of thrombosis and haemostasis
container_volume 10
creator VERHOEF, T. I.
REDEKOP, W. K.
HEGAZY, H.
DE BOER, A.
MAITLAND‐van der ZEE, A. H.
description Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland‐van der Zee AH, on behalf of the EU‐PACT group. Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012; 10: 2610–2.
doi_str_mv 10.1111/jth.12007
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1282837779</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2840435581</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3887-3027351eda7ea4c0883d502a43d65390ddf8a4f3d0b9ff0339dabed83b01cf733</originalsourceid><addsrcrecordid>eNp1kM1KAzEURoMoWqsLX0ACbnTRmuTONJmlDGrVgiL-4GpIJzftlM6kTmaQ7nwEn9EnMVp1IZhNPsjhy72HkD3O-jyc41kz7XPBmFwjHR6D6kkFg_WfnABskW3vZ4zxJBZsk2wJYHwQC94hjyNXTd5f3xqsS6qrpsidnrTzkChai3njqbM0fboRaRLeDX24ur5NOZ1g5ZrlAj0tKrqYYrWoXe7a0lW09Vj7HbJh9dzj7vfdJfdnp3fpsDe6Pr9IT0a9HJSSPWBCQszRaIk6yplSYGImdARmEEPCjLFKRxYMGyfWMoDE6DEaBWPGcysBuuRw1Rv-f27RN1lZ-BznYQN0rc-4UEKBlMFClxz8QWeuraswXaBAqghYHAXqaEXltfO-Rpst6qLU9TLjLPu0nQXb2ZftwO5_N7bjEs0v-aM3AMcr4KWY4_L_puzybriq_AA-woh2</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1237843054</pqid></control><display><type>article</type><title>Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>VERHOEF, T. I. ; REDEKOP, W. K. ; HEGAZY, H. ; DE BOER, A. ; MAITLAND‐van der ZEE, A. H.</creator><creatorcontrib>VERHOEF, T. I. ; REDEKOP, W. K. ; HEGAZY, H. ; DE BOER, A. ; MAITLAND‐van der ZEE, A. H. ; EU-PACT group</creatorcontrib><description>Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland‐van der Zee AH, on behalf of the EU‐PACT group. Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012; 10: 2610–2.</description><identifier>ISSN: 1538-7933</identifier><identifier>ISSN: 1538-7836</identifier><identifier>EISSN: 1538-7836</identifier><identifier>DOI: 10.1111/jth.12007</identifier><identifier>PMID: 23016521</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Anticoagulants ; Anticoagulants - therapeutic use ; Aryl Hydrocarbon Hydroxylases - genetics ; Cytochrome P-450 CYP2C9 ; Genotype ; Humans ; Mixed Function Oxygenases - genetics ; Phenprocoumon - therapeutic use ; Vitamin K Epoxide Reductases</subject><ispartof>Journal of thrombosis and haemostasis, 2012-12, Vol.10 (12), p.2610-2612</ispartof><rights>2012 International Society on Thrombosis and Haemostasis</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3887-3027351eda7ea4c0883d502a43d65390ddf8a4f3d0b9ff0339dabed83b01cf733</citedby><cites>FETCH-LOGICAL-c3887-3027351eda7ea4c0883d502a43d65390ddf8a4f3d0b9ff0339dabed83b01cf733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23016521$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>VERHOEF, T. I.</creatorcontrib><creatorcontrib>REDEKOP, W. K.</creatorcontrib><creatorcontrib>HEGAZY, H.</creatorcontrib><creatorcontrib>DE BOER, A.</creatorcontrib><creatorcontrib>MAITLAND‐van der ZEE, A. H.</creatorcontrib><creatorcontrib>EU-PACT group</creatorcontrib><title>Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users</title><title>Journal of thrombosis and haemostasis</title><addtitle>J Thromb Haemost</addtitle><description>Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland‐van der Zee AH, on behalf of the EU‐PACT group. Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012; 10: 2610–2.</description><subject>Anticoagulants</subject><subject>Anticoagulants - therapeutic use</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Cytochrome P-450 CYP2C9</subject><subject>Genotype</subject><subject>Humans</subject><subject>Mixed Function Oxygenases - genetics</subject><subject>Phenprocoumon - therapeutic use</subject><subject>Vitamin K Epoxide Reductases</subject><issn>1538-7933</issn><issn>1538-7836</issn><issn>1538-7836</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1KAzEURoMoWqsLX0ACbnTRmuTONJmlDGrVgiL-4GpIJzftlM6kTmaQ7nwEn9EnMVp1IZhNPsjhy72HkD3O-jyc41kz7XPBmFwjHR6D6kkFg_WfnABskW3vZ4zxJBZsk2wJYHwQC94hjyNXTd5f3xqsS6qrpsidnrTzkChai3njqbM0fboRaRLeDX24ur5NOZ1g5ZrlAj0tKrqYYrWoXe7a0lW09Vj7HbJh9dzj7vfdJfdnp3fpsDe6Pr9IT0a9HJSSPWBCQszRaIk6yplSYGImdARmEEPCjLFKRxYMGyfWMoDE6DEaBWPGcysBuuRw1Rv-f27RN1lZ-BznYQN0rc-4UEKBlMFClxz8QWeuraswXaBAqghYHAXqaEXltfO-Rpst6qLU9TLjLPu0nQXb2ZftwO5_N7bjEs0v-aM3AMcr4KWY4_L_puzybriq_AA-woh2</recordid><startdate>201212</startdate><enddate>201212</enddate><creator>VERHOEF, T. I.</creator><creator>REDEKOP, W. K.</creator><creator>HEGAZY, H.</creator><creator>DE BOER, A.</creator><creator>MAITLAND‐van der ZEE, A. H.</creator><general>Blackwell Publishing Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201212</creationdate><title>Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users</title><author>VERHOEF, T. I. ; REDEKOP, W. K. ; HEGAZY, H. ; DE BOER, A. ; MAITLAND‐van der ZEE, A. H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3887-3027351eda7ea4c0883d502a43d65390ddf8a4f3d0b9ff0339dabed83b01cf733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anticoagulants</topic><topic>Anticoagulants - therapeutic use</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Cytochrome P-450 CYP2C9</topic><topic>Genotype</topic><topic>Humans</topic><topic>Mixed Function Oxygenases - genetics</topic><topic>Phenprocoumon - therapeutic use</topic><topic>Vitamin K Epoxide Reductases</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>VERHOEF, T. I.</creatorcontrib><creatorcontrib>REDEKOP, W. K.</creatorcontrib><creatorcontrib>HEGAZY, H.</creatorcontrib><creatorcontrib>DE BOER, A.</creatorcontrib><creatorcontrib>MAITLAND‐van der ZEE, A. H.</creatorcontrib><creatorcontrib>EU-PACT group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of thrombosis and haemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>VERHOEF, T. I.</au><au>REDEKOP, W. K.</au><au>HEGAZY, H.</au><au>DE BOER, A.</au><au>MAITLAND‐van der ZEE, A. H.</au><aucorp>EU-PACT group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users</atitle><jtitle>Journal of thrombosis and haemostasis</jtitle><addtitle>J Thromb Haemost</addtitle><date>2012-12</date><risdate>2012</risdate><volume>10</volume><issue>12</issue><spage>2610</spage><epage>2612</epage><pages>2610-2612</pages><issn>1538-7933</issn><issn>1538-7836</issn><eissn>1538-7836</eissn><abstract>Verhoef TI, Redekop WK, Hegazy H, de Boer A, Maitland‐van der Zee AH, on behalf of the EU‐PACT group. Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users. J Thromb Haemost 2012; 10: 2610–2.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>23016521</pmid><doi>10.1111/jth.12007</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1538-7933
ispartof Journal of thrombosis and haemostasis, 2012-12, Vol.10 (12), p.2610-2612
issn 1538-7933
1538-7836
1538-7836
language eng
recordid cdi_proquest_miscellaneous_1282837779
source MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection
subjects Anticoagulants
Anticoagulants - therapeutic use
Aryl Hydrocarbon Hydroxylases - genetics
Cytochrome P-450 CYP2C9
Genotype
Humans
Mixed Function Oxygenases - genetics
Phenprocoumon - therapeutic use
Vitamin K Epoxide Reductases
title Long‐term anticoagulant effects of CYP2C9 and VKORC1 genotypes in phenprocoumon users
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T09%3A46%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Long%E2%80%90term%20anticoagulant%20effects%20of%20CYP2C9%20and%20VKORC1%20genotypes%20in%20phenprocoumon%20users&rft.jtitle=Journal%20of%20thrombosis%20and%20haemostasis&rft.au=VERHOEF,%20T.%20I.&rft.aucorp=EU-PACT%20group&rft.date=2012-12&rft.volume=10&rft.issue=12&rft.spage=2610&rft.epage=2612&rft.pages=2610-2612&rft.issn=1538-7933&rft.eissn=1538-7836&rft_id=info:doi/10.1111/jth.12007&rft_dat=%3Cproquest_cross%3E2840435581%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1237843054&rft_id=info:pmid/23016521&rfr_iscdi=true